



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034,
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

10th May, 2017

Corporate Relationship Department
M/s. BSE Ltd
Dalal Sreet, Fort
Mumbai 400 001

Manager – Listing
M/s. National Stock Exchange of India Ltd
“Exchange Plaza”, Bandra – Kurla Complex
Bandra (E) Mumbai 400 051

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir

Please find enclose herewith the Press Release for your information.

Thanking you

Yours faithfully
For NATCO Pharma Limited

A handwritten signature in black ink that reads "M. Adinarayana".

M. Adinarayana
Company Secretary &
Vice President (Legal & Corp. Affairs)



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034,
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Ref:PR/02/2017

Press Release

**NATCO launches POMALID, first generic version of pomalidomide capsules,
for treatment of a specific blood cancer, in INDIA**

Hyderabad, India, May 10th, 2017

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) announced today that it has launched a generic version of pomalidomide 1 mg, 2 mg, and 4 mg capsules in India. Pomalidomide is sold by Celgene Inc., in the USA, under the brand name POMALYST®.

Pomalidomide is a thalidomide analogue indicated, in combination with dexamethasone, for patients with multiple myeloma (a type of blood cancer) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.

Natco will market generic pomalidomide capsules under its brand name POMALID in India. Natco priced its generic medicine of POMALID 1 mg, 2 mg, and 4 mg capsules at an MRP of INR 5000/-, INR 10,000/-, and INR 20,000/- respectively for a monthly pack of 21 capsules. We believe, this is approximately 98% discount of price from what it is sold at in the USA to patients, per secondary market data researched

Forwarded for favour of publication
For **NATCO Pharma Limited**

M. Adinarayana

M. Adinarayana
Company Secretary &
Vice President (Legal & Corp. Affairs)